분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2011-11-02 23:21:19 , Hit : 2576
 GlaxoSmithKline is first partner for new Alnylam platform

Tuesday, November 1, 2011

By Rodney H. Brown

Alnylam Pharmaceuticals Inc. reports it has entered into a collaboration deal with GlaxoSmithKline (GSK) in which the U.K. pharmaceutical giant will use Alnylam’s new VaxiRNA enhanced virus production platform in the development of certain GSK vaccine products, such as a vaccine for influenza.

In a release, Alnylam (Nasdaq: ALNY) said that GSK will provide funding to Alnylam, which could also receive certain milestone payments, although the amounts of either were not disclosed. If the VaxiRNA platform is used in manufacturing a commercial product, Alnylam will get unspecified payments on unit product sales of that product. GSK, which is the first company to ink a deal with Alnylam for the new platform, also has an option to apply the VaxiRNA platform toward two additional vaccine products, according to the release.

John Maraganore, CEO of Alnylam, said in a statement that the VaxiRNA platform uses siRNA (small interfering RNA) technology to ramp up the output of viral vaccines, which “can become an enabling technology for the broader vaccine industry.” Specifically, the VaxiRNA platform uses siRNAs to silence specific genes that “limit or prevent efficient growth of viruses in vaccine manufacturing systems, including those in cell culture and also in eggs.”

Alnylam also uses its platform technology to work on its own drug candidates, and last month it reported it had begun a Phase 1 clinical trial of ALN-PCS, its RNAi-based treatment of severe hypercholesterolemia. The Phase 1 trials are being conducted in the U.K. on 32 patients, with results expected by the end of 2011.

In August, Alnylam completed a Phase 1 study of its liver cancer drug target, ALN-VSP, with positive results.








827   Vertex study will evaluate 12-week treatment period for some hepatitis C patients  이성욱 2011/10/25 2884
826   MicroRNAs Prevent Cell Reprogramming  이성욱 2011/10/27 3639
825   Going Viral  이성욱 2011/10/28 2659
  GlaxoSmithKline is first partner for new Alnylam platform  이성욱 2011/11/02 2576
823   Do Bacteria Age? Biologists Discover the Answer Follows Simple Economics  이성욱 2011/11/04 2435
822   Regular Aspirin Intake Halves Cancer Risk, Study Finds  이성욱 2011/11/04 2397
821   Gene Therapy Shows Promise as Hemophilia Treatment in Animal Studies  이성욱 2011/11/10 2482
820   How Blood Cells Thwart Malaria  이성욱 2011/11/13 3413
819   Pox Vaccine Treats Liver Cancer - Smallpox vaccine extends life in cancer trial-  이성욱 2011/11/13 2685
818   AASLD: African-Americans Face Hep C 'Triple Whammy'  이성욱 2011/11/17 2403
817   Uncovering a Key Player in Metastasis  이성욱 2011/11/21 2607
816   Finger (mal)formation reveals surprise function of desert DNA  이성욱 2011/11/28 2762
815   Stem-cell pioneer bows out  이성욱 2011/11/28 2481
814   Genetic variant linked to development of liver cancer in hepatitis C virus carriers  이성욱 2011/12/03 2661
813   Treatment for Blood Disease Is Gene Therapy Landmark  이성욱 2011/12/13 2026
812   Vertex begins joint studies on hepatitis C compounds  이성욱 2011/12/13 2667
811   Former Reginans changing the future of HIV  이성욱 2011/12/28 2305
810   The RNA roots of obesity?  이성욱 2012/01/03 2288
809   Alnylam Cuts One-Third of Workforce, To Save Cash for RNAi Clinical Plans  이성욱 2012/01/22 2485
808   Can DNA Self-replicate?  이성욱 2012/01/22 2491

[이전 10개] [1]..[21][22] 23 [24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN